Interacciones de Clopidogrel

CIBINQO is contraindicated in patients taking antiplatelet therapies, except for low-dose aspirin (≤81 mg daily), during the first 3 months of treatment [see Warnings and Precautions (5.7) , Drug Interactions (7.2) , and Clinical Pharmacology (12.2) ]. (etiqueta de Abrocitinib, Contraindicaciones)

…hematomas in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants • a history of traumatic or repeated epidural or spinal punctures • a history of spinal deformity or spinal surgery • optimal timing between… (etiqueta de Apixabán, Advertencia en recuadro)

Antiplatelets: ticagrelor ↑ ticagrelor Coadministration with ticagrelor is not recommended due to potential increase in the risk of dyspnea, bleeding and other adverse events associated with ticagrelor. clopidogrel ↓ clopidogrel active metabolite Coadministration of REYATAZ (with or without ritonavir) and clopidogrel is not recommended. (etiqueta de Atazanavir, Interacciones medicamentosas)

Coadministration of bupropion hydrochloride extended-release tablets (XL) with ticlopidine or clopidogrel is not recommended (7.1). (etiqueta de Bupropión, Interacciones medicamentosas)

Clopidogrel: Do not administer during KENGREAL infusion. (etiqueta de Cangrelor, Interacciones medicamentosas)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (etiqueta de Clopidogrel, Advertencias y precauciones)

As a precaution, avoid concomitant use of strong CYP2C19 inducers [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (etiqueta de Clopidogrel, Advertencias y precauciones)

Celecoxib 100 mg twice daily was non-inferior to naproxen 375 to 500 mg twice daily and ibuprofen 600 to 800 mg three times daily for the composite endpoint of the Antiplatelet Trialists' Collaboration (APTC), which consists of cardiovascular death (including hemorrhagic death), non-fatal myocardial infarction, and non-fatal stroke [ see Clinical Studies (14.5)… (etiqueta de Celecoxib, Advertencias y precauciones)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (etiqueta de Clopidogrel, Advertencias y precauciones)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (etiqueta de Clopidogrel, Advertencias y precauciones)

Table 2: Oral drugs that can be administered concomitantly with Ferric Citrate Tablets Amlodipine Aspirin Atorvastatin Calcitriol Clopidogrel Digoxin Diltiazem Doxercalciferol Enalapril Fluvastatin Glimepiride Levofloxacin Losartan Metoprolol Pravastatin Propranolol Sitagliptin Warfarin Oral drugs that have to be separated from Ferric Citrate Tablets and meals… (etiqueta de Citrato férrico, Interacciones medicamentosas)

…hematomas in these patients include: use of indwelling epidural catheters concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants a history of traumatic or repeated epidural or spinal punctures a history of spinal deformity or spinal surgery optimal timing between the… (etiqueta de Dabigatrán, Advertencia en recuadro)

…hematomas in these patients include: use of indwelling epidural catheters concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants a history of traumatic or repeated epidural or spinal punctures a history of spinal deformity or spinal surgery optimal timing between the… (etiqueta de Edoxabán, Advertencia en recuadro)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (etiqueta de Clopidogrel, Advertencias y precauciones)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (etiqueta de Clopidogrel, Advertencias y precauciones)

Antiplatelets: ticagrelor ↑ ticagrelor Coadminstration with ticagrelor is not recommended. clopidogrel ↓ clopidogrel active metabolite Coadministration with clopidogrel is not recommended due to protential reduction of the antiplatelet activity of clopidogrel. (etiqueta de Elvitegravir, cobicistat, emtricitabina y tenofovir, Interacciones medicamentosas)

…hematomas in these patients include: Use of indwelling epidural catheters Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, and other anticoagulants A history of traumatic or repeated epidural or spinal punctures A history of spinal deformity or spinal surgery Optimal timing between… (etiqueta de Enoxaparina, Advertencia en recuadro)

Avoid concomitant use of Plavix with omeprazole or esomeprazole because both significantly reduce the antiplatelet activity of Plavix [see Drug Interactions (7.1) ] . (etiqueta de Clopidogrel, Advertencias y precauciones)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (etiqueta de Clopidogrel, Advertencias y precauciones)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (etiqueta de Clopidogrel, Advertencias y precauciones)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (etiqueta de Clopidogrel, Advertencias y precauciones)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (etiqueta de Clopidogrel, Advertencias y precauciones)

…in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, or other anticoagulants • a history of traumatic or repeated epidural or spinal puncture • a history of spinal deformity or spinal surgery • Optimal timing between… (etiqueta de Fondaparinux, Advertencia en recuadro)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (etiqueta de Clopidogrel, Advertencias y precauciones)

Anticoagulants and Antiplatelets Ticagrelor Contraindicated during and 2 weeks after TOLSURA treatment. (etiqueta de Itraconazol, Interacciones medicamentosas)

As a precaution, avoid concomitant use of strong CYP2C19 inducers [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (etiqueta de Clopidogrel, Advertencias y precauciones)

As a precaution, avoid concomitant use of strong CYP2C19 inducers [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (etiqueta de Clopidogrel, Advertencias y precauciones)

Avoid concomitant use of Plavix with omeprazole or esomeprazole because both significantly reduce the antiplatelet activity of Plavix [see Drug Interactions (7.1) ] . (etiqueta de Clopidogrel, Advertencias y precauciones)

Cardiovascular agents aliskiren, ticagrelor, vorapaxar clopidogrel ↑ aliskiren ↑ ticagrelor ↑ vorapaxar ↓ clopidogrel active metabolite Avoid concomitant use with PAXLOVID. cilostazol ↑ cilostazol Dosage adjustment of cilostazol is recommended. (etiqueta de Nirmatrelvir y ritonavir, Interacciones medicamentosas)

Avoid concomitant use of Plavix with omeprazole or esomeprazole because both significantly reduce the antiplatelet activity of Plavix [see Drug Interactions (7.1) ] . (etiqueta de Clopidogrel, Advertencias y precauciones)

Avoid concomitant use of Plavix with omeprazole or esomeprazole because both significantly reduce the antiplatelet activity of Plavix [see Drug Interactions (7.1) ] . (etiqueta de Clopidogrel, Advertencias y precauciones)

…TR ial to Assess I mprovement in T herapeutic Outcomes by O ptimizing Platelet Inhibitio N with Prasugrel), patients with a history of TIA or ischemic stroke (>3 months prior to enrollment) had a higher rate of stroke on Effient (6.5%; of which 4.2% were thrombotic stroke and 2.3% were intracranial hemorrhage [ICH]) than on clopidogrel (1.2%; all thrombotic). (etiqueta de Prasugrel, Contraindicaciones)

Avoid concomitant use of repaglinide with Plavix. (etiqueta de Clopidogrel, Interacciones medicamentosas)

As a precaution, avoid concomitant use of strong CYP2C19 inducers [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (etiqueta de Clopidogrel, Advertencias y precauciones)

As a precaution, avoid concomitant use of strong CYP2C19 inducers [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (etiqueta de Clopidogrel, Advertencias y precauciones)

…in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants • a history of traumatic or repeated epidural or spinal punctures • a history of spinal deformity or spinal surgery • optimal timing between… (etiqueta de Rivaroxabán, Advertencia en recuadro)

WARNING: BLEEDING RISK • BRILINTA, like other antiplatelet agents, can cause significant, sometimes fatal bleeding ( 5.1 , 6.1 ). (etiqueta de Ticagrelor, Advertencia en recuadro)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (etiqueta de Clopidogrel, Advertencias y precauciones)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (etiqueta de Clopidogrel, Advertencias y precauciones)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (etiqueta de Clopidogrel, Advertencias y precauciones)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (etiqueta de Clopidogrel, Advertencias y precauciones)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (etiqueta de Clopidogrel, Advertencias y precauciones)

Anticoagulants and antiplatelet drugs increase the risk of bleeding if administered prior to, during, or after Activase therapy. (etiqueta de Alteplasa, Interacciones medicamentosas)

Monitor patients for bleeding, including those receiving concomitant therapy with other drugs known to cause bleeding (e.g., anticoagulants, PDE3 inhibitors, NSAIDs, antiplatelet agents, selective serotonin reuptake inhibitors) [see Drug Interactions (7.3) , Clinical Pharmacology (12.3) ] . (etiqueta de Anagrelida, Advertencias y precauciones)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (etiqueta de Clopidogrel, Advertencias y precauciones)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Opioids: Decreased exposure to clopidogrel. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (etiqueta de Clopidogrel, Advertencias y precauciones)

Opioids: Decreased exposure to clopidogrel. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Opioids: Decreased exposure to clopidogrel. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (etiqueta de Clopidogrel, Advertencias y precauciones)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (etiqueta de Clopidogrel, Advertencias y precauciones)

Opioids: Decreased exposure to clopidogrel. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Opioids: Decreased exposure to clopidogrel. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Other Antiplatelet Agents: Increases the risk of bleeding due to an additive effect. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Opioids: Decreased exposure to clopidogrel. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Dexlansoprazole, lansoprazole, and pantoprazole had less effect on the antiplatelet activity of Plavix than did omeprazole or esomeprazole [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3) ] . (etiqueta de Clopidogrel, Interacciones medicamentosas)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (etiqueta de Clopidogrel, Advertencias y precauciones)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (etiqueta de Clopidogrel, Advertencias y precauciones)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (etiqueta de Clopidogrel, Advertencias y precauciones)

Other Antiplatelet Agents: Increases the risk of bleeding due to an additive effect. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Opioids: Decreased exposure to clopidogrel. (etiqueta de Clopidogrel, Interacciones medicamentosas)

When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (etiqueta de Epoprostenol, Interacciones medicamentosas)

Other Antiplatelet Agents: Increases the risk of bleeding due to an additive effect. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (etiqueta de Clopidogrel, Advertencias y precauciones)

Carbamazepine, felbamate, lamotrigine, topiramate, oxcarbazepine, lacosamide Antilipidemic agents Atorvastatin, fluvastatin, simvastatin Antiplatelets Ticagrelor Antiviral agents Efavirenz, lopinavir/ritonavir, indinavir, nelfinavir, ritonavir, saquinavir Fosamprenavir: phenytoin when given with fosamprenavir alone may decrease the concentration of amprenavir,… (etiqueta de Fenitoína, Interacciones medicamentosas)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (etiqueta de Clopidogrel, Advertencias y precauciones)

Opioids: Decreased exposure to clopidogrel. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (etiqueta de Clopidogrel, Advertencias y precauciones)

Carbamazepine, felbamate, lamotrigine, topiramate, oxcarbazepine, lacosamide Antiplatelets Ticagrelor Antilipidemic agents Atorvastatin, fluvastatin, simvastatin Antiviral agents Efavirenz, lopinavir/ritonavir, indinavir, nelfinavir, ritonavir, saquinavir Fosamprenavir: phenytoin when given with fosamprenavir alone may decrease the concentration of amprenavir,… (etiqueta de Fosfenitoína, Interacciones medicamentosas)

El ginkgo biloba puede aumentar el riesgo de sangrado cuando se toma con medicamentos anticoagulantes o antiagregantes plaquetarios. (NCCIH, Ginkgo)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (etiqueta de Clopidogrel, Advertencias y precauciones)

Opioids: Decreased exposure to clopidogrel. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (etiqueta de Clopidogrel, Advertencias y precauciones)

Opioids: Decreased exposure to clopidogrel. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Opioids: Decreased exposure to clopidogrel. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Opioids: Decreased exposure to clopidogrel. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Opioids: Decreased exposure to clopidogrel. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (etiqueta de Clopidogrel, Advertencias y precauciones)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (etiqueta de Clopidogrel, Advertencias y precauciones)

The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin. (etiqueta de Icosapento de etilo, Advertencias y precauciones)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (etiqueta de Clopidogrel, Advertencias y precauciones)

Anticoagulants and Antiplatelet Drugs rivaroxaban cilostazol, coumarins, dabigatran Cilostazol: Concomitant administration of single doses of cilostazol 100 mg and ketoconazole 400 mg approximately doubled cilostazol concentrations and altered (increase/decrease) the concentrations of the active metabolites of cilostazol. (etiqueta de Ketoconazol, Interacciones medicamentosas)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (etiqueta de Clopidogrel, Advertencias y precauciones)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (etiqueta de Clopidogrel, Advertencias y precauciones)

Dexlansoprazole, lansoprazole, and pantoprazole had less effect on the antiplatelet activity of Plavix than did omeprazole or esomeprazole [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3) ] . (etiqueta de Clopidogrel, Interacciones medicamentosas)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Opioids: Decreased exposure to clopidogrel. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (etiqueta de Clopidogrel, Advertencias y precauciones)

Opioids: Decreased exposure to clopidogrel. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Misoprostol does not exert clinically significant effects on the absorption, blood levels, and antiplatelet effects of therapeutic doses of aspirin. (etiqueta de Misoprostol, Interacciones medicamentosas)

Consider the use of a parenteral antiplatelet agent in acute coronary syndrome patients requiring coadministration of morphine or other opioid agonists. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (etiqueta de Clopidogrel, Advertencias y precauciones)

Opioids: Decreased exposure to clopidogrel. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Concomitant Treatment with CYP2B6 Inhibitors (e.g., ticlopidine or clopidogrel) can increase bupropion exposure. (etiqueta de Naltrexona y bupropión, Interacciones medicamentosas)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (etiqueta de Clopidogrel, Advertencias y precauciones)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Opioids: Decreased exposure to clopidogrel. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (etiqueta de Clopidogrel, Advertencias y precauciones)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (etiqueta de Clopidogrel, Advertencias y precauciones)

Opioids: Decreased exposure to clopidogrel. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Opioids: Decreased exposure to clopidogrel. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Opioids: Decreased exposure to clopidogrel. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Dexlansoprazole, lansoprazole, and pantoprazole had less effect on the antiplatelet activity of Plavix than did omeprazole or esomeprazole [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3) ] . (etiqueta de Clopidogrel, Interacciones medicamentosas)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (etiqueta de Clopidogrel, Advertencias y precauciones)

Opioids: Decreased exposure to clopidogrel. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Opioids: Decreased exposure to clopidogrel. (etiqueta de Clopidogrel, Interacciones medicamentosas)

DRUG INTERACTIONS Bleeding has been reported in patients treated with pentoxifylline extended-release tablets with or without concomitant NSAIDs, anticoagulants, or platelet aggregation inhibitors. (etiqueta de Pentoxifilina, Interacciones medicamentosas)

Opioids: Decreased exposure to clopidogrel. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (etiqueta de Clopidogrel, Advertencias y precauciones)

Opioids: Decreased exposure to clopidogrel. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Opioids: Decreased exposure to clopidogrel. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (etiqueta de Clopidogrel, Advertencias y precauciones)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (etiqueta de Clopidogrel, Advertencias y precauciones)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (etiqueta de Clopidogrel, Advertencias y precauciones)

Opioids: Decreased exposure to clopidogrel. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Should serious bleeding that is not controlled by local pressure occur, discontinue any concomitant heparin or antiplatelet agents immediately and treat appropriately. (etiqueta de Tenecteplasa, Advertencias y precauciones)

Other Antiplatelet Agents: Increases the risk of bleeding due to an additive effect. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (etiqueta de Clopidogrel, Advertencias y precauciones)

Opioids: Decreased exposure to clopidogrel. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Opioids: Decreased exposure to clopidogrel. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (etiqueta de Trazodona, Advertencias y precauciones)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (etiqueta de Clopidogrel, Interacciones medicamentosas)

La vitamina E puede inhibir la agregación plaquetaria y la coagulación dependiente de la vitamina K, lo que aumenta el riesgo de sangrado con los fármacos anticoagulantes y antiagregantes plaquetarios. (NIH Office of Dietary Supplements, Vitamin E)

• Increased Risk of Bleeding : Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, or other drugs that affect coagulation may increase risk ( 5.3 ). (etiqueta de Vortioxetina, Advertencias y precauciones)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Los suplementos de omega-3 pueden prolongar levemente el tiempo de sangrado; la combinación con anticoagulantes como la warfarina justifica un seguimiento, aunque no se ha demostrado de forma constante un sangrado clínicamente significativo. (NIH Office of Dietary Supplements, Omega-3 Fatty Acids)

Los suplementos de ajo pueden aumentar el riesgo de sangrado con anticoagulantes como la warfarina. (NCCIH, Garlic)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (etiqueta de Clopidogrel, Interacciones medicamentosas)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Repaglinide (CYP2C8 Substrates) The acyl-β-glucuronide metabolite of clopidogrel is a strong inhibitor of CYP2C8. (etiqueta de Clopidogrel, Interacciones medicamentosas)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (etiqueta de Clopidogrel, Interacciones medicamentosas)

If possible, assess the presence of drug-dependent antiplatelet antibodies. (etiqueta de Etosuximida, Advertencias)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (etiqueta de Clopidogrel, Interacciones medicamentosas)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Repaglinide (CYP2C8 Substrates) The acyl-β-glucuronide metabolite of clopidogrel is a strong inhibitor of CYP2C8. (etiqueta de Clopidogrel, Interacciones medicamentosas)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (etiqueta de Clopidogrel, Interacciones medicamentosas)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (etiqueta de Clopidogrel, Interacciones medicamentosas)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Repaglinide (CYP2C8 Substrates) The acyl-β-glucuronide metabolite of clopidogrel is a strong inhibitor of CYP2C8. (etiqueta de Clopidogrel, Interacciones medicamentosas)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Repaglinide (CYP2C8 Substrates) The acyl-β-glucuronide metabolite of clopidogrel is a strong inhibitor of CYP2C8. (etiqueta de Clopidogrel, Interacciones medicamentosas)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (etiqueta de Clopidogrel, Interacciones medicamentosas)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (etiqueta de Clopidogrel, Interacciones medicamentosas)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (etiqueta de Clopidogrel, Interacciones medicamentosas)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Platelet aggregation inhibitor: ticagrelor ↑ ticagrelor Co-administration of PREZISTA/ritonavir and ticagrelor is not recommended. clopidogrel ↓ clopidogrel active metabolite Co-administration of PREZISTA/ritonavir and clopidogrel is not recommended due to potential reduction of the antiplatelet activity of clopidogrel. prasugrel ↔ prasugrel active metabolite… (etiqueta de Darunavir, Interacciones medicamentosas)

Platelet aggregation inhibitor: ticagrelor ↑ ticagrelor Co-administration of PREZCOBIX or PREZCOBIX PED and ticagrelor is not recommended. clopidogrel ↓ clopidogrel active metabolite Co-administration of PREZCOBIX or PREZCOBIX PED with clopidogrel is not recommended due to the potential reduction of the antiplatelet activity of clopidogrel. prasugrel ↔ prasugrel… (etiqueta de Darunavir y cobicistat, Interacciones medicamentosas)

Platelet Aggregation Inhibitors Clopidogrel: No clinically significant pharmacodynamic interactions were observed when clopidogrel was co-administered with nifedipine. (etiqueta de Nifedipino, Interacciones medicamentosas)